Finkelstein Thompson LLP Announces Investigation of IDM Pharma, Inc.

WASHINGTON, May 20, 2009 (GLOBE NEWSWIRE) - LawFuel.com Legal Newswire Service - Finkelstein Thompson LLP is investigating potential shareholder claims arising from the proposed acquisition of IDM Pharma, Inc. ("IDM" or the "Company") (Nasdaq:IDMI) by Takeda Pharmaceutical Co. Under the terms of the merger agreement, IDM shareholders will receive $2.64 per share, valuing the transaction at approximately $66.7 million. The investigation is focused on the potential unfairness of the merger price and of the process by which the IDM Board of Directors approved the agreement. If you are interested in discussing your rights as an IDM shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at contact@finkelsteinthompson.com. Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com.

Finkelstein Thompson LLP Announces Investigation of IDM Pharma, Inc.

About The Author

Law Admin

Subscibe to LawFuel

About The Author

Law Admin

Read More